Related Experiment Videos

[Lipid lowering after percutaneous coronary intervention. Intended and achieved treatment goals in real life]

Alfried Germing1, Michael Lindstaedt, Andreas Mügge

  • 1Medizinische Klinik II, Kardiologie und Angiologie, Berufsgenossenschaftliche Kliniken Bergmannsheil, Ruhr-Universität Bochum, Bürkle-de-la-Camp-Platz 1, 44789 Bochum. alfried.germing@ruhr-uni-bochum.de

Medizinische Klinik (Munich, Germany : 1983)
|February 3, 2006
PubMed

Insights

Patients after coronary revascularization often do not achieve guideline-directed lipid levels despite treatment. Ineffective lipid-lowering drug management, particularly lack of dosage adjustments, is a key issue.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Dyslipidemia is a significant risk factor for coronary artery disease (CAD) development and progression.
  • Lipid-lowering drug therapy is crucial for patients post-coronary revascularization.
  • Current guidelines recommend specific lipid level targets, but real-world achievement often falls short.

Purpose of the Study:

  • To analyze lipid level dynamics and lipid-lowering drug management in patients undergoing percutaneous coronary intervention (PCI).
  • To assess the achievement of guideline-oriented lipid levels in high-risk patients post-revascularization.

Main Methods:

  • Prospective analysis of lipid profiles (total cholesterol, LDL, HDL, triglycerides) and drug dosages over 5.5 months.
  • Inclusion of patients undergoing percutaneous coronary intervention (PCI).
  • Evaluation of treatment adherence and dosage modifications during follow-up.

Main Results:

  • Only 49.8% of patients were on lipid-lowering drugs at the time of PCI.
  • Lipid-lowering drug dosages were rarely modified during the 5.5-month follow-up period.
  • Despite 87.5% of patients receiving treatment at follow-up, only 32.5% achieved guideline-oriented lipid levels.

Conclusions:

  • Hypercholesterolemia treatment is often ineffective in high-risk patients post-coronary revascularization.
  • A significant barrier to effective treatment is the lack of lipid-lowering drug dosage adjustments.
  • Improved collaboration between hospitals and general practitioners is needed to optimize lipid management and reduce cardiovascular events.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...